-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Named to the 2025 Top 100 Chinese Pharmaceutical Companies List
Category:
发布时间：2026-03-19
【概要描述】
On the afternoon of March 18, at the MDS 2026 Fourth Pharmaceutical Marketing Big Data Summit held in the mountain city of Chongqing, Zhongmeng Big Data and Yaozhi Network jointly released the 2025 Top 100 Chinese Pharmaceutical Companies Ranking and simultaneously unveiled the China Pharmaceutical Retail Rankings. Shijiazhuang Sihua Pharmaceutical Group, thanks to its sustained and steady market influence, was successfully included in the 2025 Chinese Pharmaceutical Market Rankings series, ranking 66th on the Overall List and 27th on the Chemical Pharmaceuticals List.
On the afternoon of March 18, at the MDS 2026 Fourth Pharmaceutical Marketing Big Data Summit held in the mountain city of Chongqing, Zhongmeng Big Data and Yaozhi Network jointly released the 2025 Top 100 Chinese Pharmaceutical Companies Ranking, along with the concurrently unveiled China Pharmaceutical Retail Rankings. Shijiazhuang Sihua Pharmaceutical Group, thanks to its sustained and steady market influence, was successfully included in the 2025 series of rankings for China’s pharmaceutical market, ranking 66th on the 2025 Overall Ranking of Chinese Pharmaceutical Companies and 27th on the 2025 Ranking of Chinese Pharmaceutical Companies Specializing in Chemical Pharmaceuticals.
According to reports, the ranking was initiated by Yaozhi Network and rigorously evaluated by an expert review committee based on companies’ 2025 end-user pharmaceutical sales data (retail plus hospital channels). It is divided into four main categories: Overall Ranking, Traditional Chinese Medicine Ranking, Chemical Pharmaceutical Ranking, and Biologic Pharmaceutical Ranking, with the aim of objectively reflecting the industry landscape and setting benchmarks for industry development.
In recent years, in the face of a severe and complex domestic and international economic environment, the Group has remained firmly focused on the paramount task of high-quality development, with an eye toward the unified national market and the dual circulation strategy—domestic and international. It has deepened the implementation of its innovation-driven strategy, continuously promoted the integrated and coordinated development of the innovation chain, talent chain, industrial chain, and supply chain, accelerated the cultivation of new productive forces, and established an industrial ecosystem characterized by innovative pharmaceuticals as the leading force, specialty chemical drug formulations and active pharmaceutical ingredients as the core, and high-end pharmaceutical packaging materials and specialized biologics as extensions. Empowered by technological innovation and digital transformation, the Group has consistently ranked among the industry leaders in the number of new product applications submitted and approved; in 2025, it secured approval for 93 new products, thereby achieving both chain-like extension and cluster-based development of its product portfolio. To date, a total of 171 drug varieties comprising 223 dosage forms have either passed or been deemed to have passed the evaluation of generic drug quality and therapeutic equivalence. Leveraging an integrated “API-plus-formulation” development model, the Company has delivered outstanding performance in national centralized procurement and renewal bids, as well as in inter-provincial alliance procurement, continuously enhancing product accessibility and market penetration.
Standing at a new starting point and anchoring a new journey, the Group’s leadership stated that during the 15th Five-Year Plan period, the Group will align itself with national strategies and market demands, focus on innovative drugs and complex formulations, strengthen basic research, continuously optimize its product portfolio, ensure smooth domestic–international dual circulation, accelerate transformation, upgrading, quality improvement, and efficiency enhancement, and thereby inject new momentum and vitality into the enterprise’s long-term development as well as the high-quality development of Shijiazhuang’s biopharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091